Immunic AG
Immunic Therapeutics to Present at the Needham Healthcare Conference on April 10
DGAP-News: Immunic AG / Key word(s): Conference Immunic Therapeutics to Present at the Needham Healthcare Conference on April 10 Planegg-Martinsried, Germany, April 2, 2019 – Immunic AG, a privately held clinical-stage biotechnology company, today announced that Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, will present at the 18th Annual Needham Healthcare Conference on Wednesday, April 10, 2019 at 4:10 pm ET at the Westin Grand Central Hotel, New York. To view the live webcast, please follow this link: http://wsw.com/webcast/needham90/immunic/. The webcast also will be available for viewing on the “News” section of Immunic’s website at: www.immunic-therapeutics.com. An archived replay will be available on the company’s website for a period of 90 days after the conference. About Immunic AG Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements relating to Immunic AG, including statements about our pending transaction with Vital Therapies, our three development programs and the targeted diseases, our existing and planned clinical trials and the clinical utility of Immunic’s therapeutic candidates. Risks and uncertainties that may cause actual results to differ materially from those expressed or implied in any forward-looking statement include, but are not limited to: the risk that the stockholders of Vital Therapies do not approve the proposed transaction with Immunic, the ability of the parties to close the proposed transaction, Immunic’s expected listing of Immunic, Inc. on NASDAQ and Immunic’s plans to develop and commercialize its product candidates, including IMU-838, IMU-935 and IMU-856; and the timing of Immunic’s planned clinical trials. Forward-looking statements are identified by the use of forward-looking terminology including “believes,” “expects,” “may,” “will,” “should,” “seeks,” “intends,” “plans,” “pro forma,” “estimates,” or “anticipates” or the negative of these words and phrases or other variations of these words and phrases or comparable terminology. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These forward-looking statements should not be relied upon as predictions of future events as Immunic cannot assure investors that the events or circumstances reflected in these statements will be achieved or will occur. The forward-looking statements in this press release represent Immunic’s views as of the date of this press release. Immunic anticipates that subsequent events and developments will cause its views to change. Immunic may elect to update these forward-looking statements at some point in the future, however, it has no current intention of doing so except to the extent required by applicable law. Investors should, therefore, not rely on these forward-looking statements as representing Immunic’s views as of any date subsequent to the date of this press release. Additional Information about the Proposed Transaction between Vital Therapies, Inc. and Immunic AG and Where to Find It This communication does not constitute a solicitation of proxy, an offer to purchase or a solicitation of an offer to sell any securities. Vital Therapies and its executive officers and directors may be deemed to be participants in the solicitation of proxies from Vital Therapies’ stockholders with respect to the matters relating to the proposed transaction. Immunic may also be deemed a participant in such solicitation. Information regarding Vital Therapies’ executive officers and directors is available in Vital Therapies’ proxy statement on Schedule 14A for its 2018 annual meeting of stockholders, filed with the SEC on April 12, 2018. Information regarding any interest that Vital Therapies, Immunic or any of the executive officers or directors of Vital Therapies or Immunic may have in the transaction with Immunic is set forth in the final proxy statement/prospectus that Vital Therapies has filed with the SEC in connection with its stockholder vote on matters relating to the proposed transaction. Contact Information Immunic AG Or
02.04.2019 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |